Congenital Heart Disease: Classification and Ventricular Septal Defect (VSD)

1. Classification of Congenital Heart Disease (CHD)

A. Acyanotic CHD

• Ventricular septal defect (VSD) — most common CHD overall
• Atrial septal defect (ASD)
• Patent ductus arteriosus (PDA)
• Atrioventricular septal defect (AVSD/endocardial cushion defect)

• Pulmonary stenosis
• Aortic stenosis
• Coarctation of aorta

B. Cyanotic CHD

• Tetralogy of Fallot
• Tricuspid atresia
• Pulmonary atresia

• Transposition of great arteries (TGA)
• Total anomalous pulmonary venous connection (TAPVC)
• Truncus arteriosus
• Single ventricle / double outlet right ventricle

2. Ventricular Septal Defect (VSD)

Anatomic Types (Ghai classification, based on location)

1. Perimembranous (paramembranous) VSD — most common (~80%), involves membranous septum, may extend into adjacent muscular septum
2. Muscular/trabecular VSD — within muscular septum, may be single or multiple ("Swiss cheese" septum)
3. Inlet (AV canal type) VSD — beneath the AV valves, often associated with AVSD/Down syndrome
4. Outlet (supracristal/subarterial/conal) VSD — below the pulmonary valve, may cause aortic cusp prolapse and aortic regurgitation

Functional classification (clinically most useful)

• Small (restrictive) VSD — defect size less than aortic annulus diameter; large pressure gradient across the defect
• Moderate VSD
• Large (non-restrictive) VSD — defect equal to or larger than aortic annulus; no significant pressure gradient between ventricles, pressures equalize

3. Hemodynamics

• Because left ventricular pressure exceeds right ventricular pressure, blood shunts left to right through the defect, mainly during systole.
• The magnitude of shunt depends on: size of the defect and relative resistances of the systemic and pulmonary circulations (PVR vs SVR).
• Small VSD: high resistance to flow across the defect (restrictive) -> small shunt, minimal hemodynamic disturbance, normal pulmonary artery pressure.
• Large VSD: little resistance to flow -> shunt volume depends entirely on the ratio of PVR to SVR.
  • At birth, PVR is high (normally); as PVR falls over the first 4-8 weeks of life, left-to-right shunt increases progressively, producing pulmonary over-circulation (Qp:Qs may reach 3:1 or more) and volume overload of the left atrium and left ventricle.
  • This produces symptoms of heart failure typically appearing at 4-8 weeks of age as PVR drops.
• Chronic large shunts with unrestricted pulmonary flow and pressure eventually cause pulmonary vascular obstructive disease (medial hypertrophy, intimal proliferation of pulmonary arterioles) -> rising PVR -> shunt decreases and may reverse (right-to-left) -> Eisenmenger syndrome, with the patient becoming cyanotic ("late cyanosis").
• A small subarterial (outlet) VSD can cause prolapse of the aortic valve cusp into the defect due to a Venturi effect, leading to progressive aortic regurgitation even though the shunt itself is small.

4. Clinical Features

• Asymptomatic; normal growth
• Loud, harsh pansystolic murmur, grade 3-4/6, best heard at left lower sternal border (LLSB), often with a thrill
• No signs of cardiac enlargement; normal S2

• Symptoms appear as pulmonary vascular resistance falls (4-8 weeks age):
  • Feeding difficulty, sweating during feeds, breathlessness, poor weight gain/failure to thrive
  • Recurrent lower respiratory tract infections/bronchopneumonia (due to pulmonary plethora)
• Signs:
  • Tachypnea, tachycardia, hepatomegaly (signs of CHF)
  • Precordial bulge, hyperdynamic apex, displaced apex (LV volume overload)
  • Pansystolic murmur at LLSB (murmur may become softer as defect becomes large/non-restrictive, or as pulmonary hypertension develops -- "the smaller the murmur, the bigger the defect and worse the physiology" once PVR rises)
  • Mid-diastolic rumble at apex (relative mitral stenosis from increased flow across mitral valve)
  • Loud P2 (pulmonary component of S2) if pulmonary hypertension present

• Cyanosis, clubbing, decreasing murmur intensity, single loud S2, right ventricular heave, no more CHF symptoms (in fact patient may feel "better" as shunt reverses) — this is a surgical contraindication.

5. Assessment of Severity

6. Complications

1. Congestive heart failure — most common complication in infancy with large VSD
2. Recurrent chest infections/failure to thrive — due to pulmonary plethora and reduced compliance
3. Infective endocarditis — increased risk, especially with small-to-moderate VSDs (turbulent jet); antibiotic prophylaxis previously advised, now per current AHA/ESC guidelines restricted to specific high-risk situations
4. Aortic regurgitation — with subarterial/outlet VSD due to cusp prolapse
5. Pulmonary vascular obstructive disease -> Eisenmenger syndrome — irreversible, occurs with long-standing large uncorrected defects, usually by 1-2 years in large non-restrictive defects if uncorrected, though timeline varies
6. Right ventricular outflow tract obstruction (acquired infundibular stenosis in some perimembranous VSDs, giving "pink tetralogy" physiology)
7. Arrhythmias in older/uncorrected or post-surgical patients
8. Growth failure/malnutrition from chronic heart failure and recurrent infections

7. Management

A. Medical Management (initial, for infants with CHF, and for defects expected to close spontaneously)

• Diuretics (furosemide ± spironolactone) to reduce pulmonary congestion
• ACE inhibitors (e.g., enalapril, captopril) to reduce afterload and left-to-right shunt
• Digoxin in some cases of significant CHF
• Nutritional support — high-calorie feeds, nasogastric feeding if needed, due to increased metabolic demand and poor feeding
• Treatment of intercurrent respiratory infections
• Iron therapy if anemia present (anemia worsens shunt physiology)

B. Watchful waiting

• Many small and even a good proportion of moderate VSDs (especially muscular VSDs) show spontaneous closure, most commonly within the first 2 years of life. Regular follow-up with clinical exam and echocardiography is advised.

C. Indications for Closure (Surgical/Catheter-based)

• Large VSD with uncontrolled CHF/failure to thrive despite medical therapy — closure in infancy (typically by 3-6 months)
• Qp:Qs > 2:1 with evidence of significant left heart volume overload
• Development of aortic regurgitation (any VSD with progressive AR should be closed even if the defect itself is small, to prevent worsening AR)
• Development of double-chambered right ventricle/infundibular obstruction
• Recurrent infective endocarditis
• Evidence of early, still-reversible pulmonary hypertension (elevated but reactive PVR) — closure should be done before PVR becomes fixed

D. Contraindication to closure

• Established Eisenmenger syndrome with fixed, irreversible elevation of PVR — closing the defect in this setting removes the "pop-off" and precipitates acute right heart failure/death. Such patients may be candidates for pulmonary vasodilator therapy (e.g., bosentan, sildenafil) or, rarely, combined heart-lung transplant.

E. Methods of closure

• Surgical closure under cardiopulmonary bypass with patch closure — standard for most moderate-large perimembranous, inlet, and outlet VSDs, and for infants with CHF
• Transcatheter device closure (e.g., Amplatzer devices) — increasingly used for select muscular VSDs and some perimembranous VSDs with adequate rims, avoiding open-heart surgery
• Pulmonary artery banding (palliative) — occasionally used as a staged procedure in small, sick infants with multiple muscular VSDs ("Swiss-cheese septum") not amenable to primary closure, to reduce pulmonary blood flow until definitive repair is feasible

F. Follow-up

• Regular follow-up post-closure for residual shunt, arrhythmia, ventricular function, and growth
• Endocarditis prophylaxis per current guidelines (generally only for the first 6 months after prosthetic patch/device closure, or if residual defect adjacent to prosthetic material)

Quick Reference Summary Table

Rheumatic Heart Disease: Diagnostic Criteria, Emergency Management of Carditis, and Follow-up

1. Diagnostic Criteria for Acute Rheumatic Fever (Revised Jones Criteria)

Essential requirement

• Positive throat culture or rapid antigen test
• Elevated or rising anti-streptolysin O (ASO) titer or anti-DNase B titer

For Initial Episode of ARF

For Recurrent ARF (in a patient with known past RF/RHD)

Major Criteria

1. Carditis — clinical and/or subclinical (echocardiographic valvulitis now accepted as evidence even without audible murmur)
2. Polyarthritis (or in moderate/high-risk populations: monoarthritis or polyarthralgia also accepted)
3. Chorea (Sydenham chorea)
4. Erythema marginatum
5. Subcutaneous nodules

Minor Criteria

• Polyarthralgia
• Fever (≥38.5°C)
• ESR ≥60 mm/hr and/or CRP ≥3.0 mg/dL
• Prolonged PR interval on ECG (age-adjusted, in absence of carditis as major criterion)

• Monoarthralgia
• Fever (≥38°C)
• ESR ≥30 mm/hr and/or CRP ≥3.0 mg/dL
• Prolonged PR interval

Special notes (Ghai emphasizes these)

• Echocardiography with Doppler is now recommended in all suspected cases of ARF, even when carditis is not clinically apparent, and can detect subclinical valvulitis (typically mitral regurgitation) — this counts as a major criterion.
• Chorea alone, or indolent carditis alone, with no other explanation, is sufficient for diagnosis without needing the full Jones criteria complement, since these have high specificity by themselves.
• The criteria are meant for diagnosis of the acute attack, not for monitoring disease activity or response to treatment.

2. Emergency Management of a 6-Year-Old with Rheumatic Carditis

Step 1: Immediate Assessment (ABC + cardiac status)

• Airway, breathing, circulation
• Vitals: heart rate, respiratory rate, blood pressure, oxygen saturation
• Look for signs of congestive heart failure: tachypnea, tachycardia, gallop rhythm, hepatomegaly, basal crepitations, raised JVP, edema, poor perfusion
• Auscultate for new/changing murmurs (mitral regurgitation murmur most common; mid-diastolic Carey Coombs murmur in severe carditis; aortic regurgitation if aortic valve involved)
• Grade severity of carditis: mild (murmur only, no cardiomegaly), moderate (cardiomegaly, no failure), severe (cardiomegaly with CHF)

Step 2: Investigations to confirm and stage

• CBC, ESR, CRP
• Throat swab culture and ASO/anti-DNase B titers
• Blood culture (to exclude infective endocarditis if murmur is new)
• Chest X-ray — cardiomegaly, pulmonary venous congestion/edema
• ECG — PR prolongation, arrhythmia
• Echocardiography (essential) — valve regurgitation (MR most common, may have AR), chamber size, ejection fraction, pericardial effusion

Step 3: Admit the child (all children with carditis need hospitalization)

Step 4: Treat Heart Failure (if present) — this takes priority in the emergency setting

• Bed rest, propped-up position, oxygen if hypoxic
• Diuretics: furosemide (IV in acute setting) ± spironolactone
• ACE inhibitors (enalapril/captopril) once stable, to reduce afterload, particularly if significant MR/AR
• Digoxin — used cautiously in rheumatic carditis (myocarditis makes the heart more sensitive to digoxin toxicity, so lower doses are used) for CHF with poor ventricular function
• Fluid and salt restriction
• Treat pulmonary edema if present (oxygen, diuretics, positioning)
• In fulminant carditis with severe valve regurgitation refractory to medical therapy, valve surgery may rarely be required emergently, but this is uncommon in initial presentation

Step 5: Eradicate the streptococcal infection

• Benzathine penicillin G 6 lakh units (for <27 kg) or 12 lakh units (for ≥27 kg) IM single dose
• Alternative: oral penicillin V for 10 days if IM injection not feasible
• If penicillin allergic: erythromycin or azithromycin

Step 6: Anti-inflammatory therapy for carditis

• Aspirin — used for arthritis/arthralgia and mild carditis; dose approximately 80-100 mg/kg/day in 4 divided doses, tapered over several weeks as inflammatory markers normalize
• Corticosteroids (oral prednisolone, approximately 1-2 mg/kg/day) — preferred over aspirin in moderate to severe carditis (cardiomegaly/CHF), continued for 2-3 weeks then tapered gradually (over 2-3 weeks) with overlap of aspirin during steroid tapering to prevent rebound inflammation
• Note (as also reflected in current rheumatology literature retrieved): evidence that steroids or aspirin alter the long-term natural history of valve damage is limited, but they are still used for symptomatic relief and control of active inflammation in standard practice, including Ghai's recommendations
• Monitor for salicylate toxicity (tinnitus, hyperventilation) with aspirin use

Step 7: Supportive care

• Strict bed rest until acute inflammation subsides (clinically and by ESR/CRP normalization), then gradual mobilization
• Monitor for chorea, arthritis, and other Jones criteria manifestations
• Nutrition support

3. Follow-up Plan

A. Secondary Prophylaxis (the cornerstone of long-term management)

• Benzathine penicillin G, IM, every 3 weeks (more frequent than the standard 4-weekly schedule is preferred in high-risk/endemic settings like India, per Ghai, because 4-weekly dosing gives inadequate protection in a proportion of children) — dose 6 lakh units if <27 kg, 12 lakh units if ≥27 kg
• Oral alternative (less effective): penicillin V 250 mg BID, or erythromycin/sulfadiazine if penicillin allergic
• Duration of secondary prophylaxis depends on presence and severity of carditis/residual valve disease:
  • No carditis: minimum 5 years after last attack or until age 18-21 years (whichever is longer)
  • Carditis but no residual valve disease: 10 years after last attack or until age 21 years (whichever is longer)
  • Carditis with residual valvular disease (persistent RHD): lifelong prophylaxis, sometimes extended into adulthood indefinitely

B. Clinical and Cardiac Follow-up

• Regular clinic visits: monthly initially, then every 3-6 months
• Serial echocardiography to monitor valve involvement and ventricular function — e.g., at discharge, 2 months, 6 months, and then annually depending on severity, per Ghai's recommended schedule for surveillance of evolving valve disease
• ECG at follow-up visits to monitor for conduction abnormalities
• Growth and nutrition monitoring

C. Monitoring for Recurrence

• Educate family to report any new fever, joint pain, or breathlessness promptly, as recurrent ARF attacks worsen valve damage cumulatively
• Screen and treat family members/close contacts for streptococcal pharyngitis if symptomatic

D. Infective Endocarditis Prophylaxis

• Advise dental and antibiotic prophylaxis prior to dental/surgical procedures in children with residual valvular lesions, per current AHA/cardiology society guidelines (amoxicillin as first-line for eligible procedures)

E. Long-term Surveillance for Valve Disease Progression

• Since RHD is progressive, children with persistent mitral or aortic regurgitation need periodic cardiology review to watch for:
  • Worsening regurgitation or development of stenosis (mitral stenosis develops over years)
  • Development of heart failure requiring escalation of medical therapy
  • Timing for valve intervention (balloon valvotomy for mitral stenosis, valve repair/replacement for severe regurgitation) if disease progresses despite adequate prophylaxis

F. Family and Community Education

• Explain the importance of strict adherence to prophylaxis (this is the single most effective measure to prevent progression to severe RHD)
• Register the child in an RHD control program/registry if available (many Indian states run RHD control programs per Ghai's public health emphasis)
• Address socioeconomic and living conditions that predispose to recurrent streptococcal infection (overcrowding, poor hygiene access)

Summary Flow for This 6-Year-Old

1. Diagnostic Criteria (Revised Jones Criteria)

• Initial episode: 2 major, OR 1 major + 2 minor criteria
• Recurrent episode: 2 major, OR 1 major + 2 minor, OR 3 minor criteria

2. Emergency Management of a 6-Year-Old with Rheumatic Carditis

1. Assess ABC + CHF status: tachypnea, tachycardia, gallop, hepatomegaly, crepitations, new/changing murmurs (MR most common; Carey Coombs mid-diastolic murmur in severe carditis)
2. Investigate: CBC, ESR, CRP, throat culture, ASO/anti-DNase B, blood culture, chest X-ray, ECG, echocardiography
3. Admit all children with carditis
4. Treat heart failure (priority): bed rest, oxygen if hypoxic, IV furosemide ± spironolactone, ACE inhibitors (enalapril/captopril) once stable, digoxin used cautiously (myocarditis increases toxicity risk) at lower doses
5. Eradicate GAS: benzathine penicillin G IM single dose (6 lakh units if <27 kg, 12 lakh units if ≥27 kg), or oral penicillin V for 10 days
6. Anti-inflammatory therapy: aspirin (~80-100 mg/kg/day) for mild carditis/arthritis; oral prednisolone (~1-2 mg/kg/day) for moderate-severe carditis (cardiomegaly/CHF), tapered over 2-3 weeks with aspirin overlap to prevent rebound
7. Supportive care: strict bed rest until inflammation subsides, nutrition, gradual mobilization

3. Follow-up Plan

• Secondary prophylaxis: benzathine penicillin G IM every 3 weeks (preferred over 4-weekly in high-risk settings like India); duration - 5 years or until 18-21 years if no carditis, 10 years or until 21 years if carditis without residual disease, lifelong if residual valvular disease persists
• Serial echocardiography (discharge, 2 months, 6 months, then annually) and ECG to track valve status and conduction
• Educate family to report fever/joint pain/breathlessness promptly; screen symptomatic close contacts for GAS
• Infective endocarditis prophylaxis for dental/surgical procedures if residual valve lesions present
• Long-term cardiology surveillance for progression to mitral stenosis or worsening regurgitation, with referral for valve intervention if needed
• Enroll in RHD control program/registry where available, and address socioeconomic factors predisposing to recurrent GAS infection